Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cyclopharm Limited ( (AU:CYC) ) has shared an announcement.
Cyclopharm Limited reported a 26% increase in revenues from ordinary activities for the half-year ended 30 June 2025, reaching $15,422,971. Despite the revenue growth, the company experienced a 2% increase in its loss after tax, amounting to $7,687,875. The announcement highlights the company’s financial performance, indicating a challenging period with higher losses despite increased revenue, which may impact its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, focusing on the development and distribution of medical and radiopharmaceutical products. The company is known for its specialized products in the field of nuclear medicine, particularly its Technegas system, which is used for lung imaging.
Average Trading Volume: 60,801
Technical Sentiment Signal: Sell
Current Market Cap: A$111.7M
See more insights into CYC stock on TipRanks’ Stock Analysis page.